Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3455970 | 0.87 | ADORA2A (0.44) | RAF1DYRK1AADORA2AMAPK13MAPK12 | |
| SCHEMBL3456079 | 0.87 | ADORA2A (0.44) | RAF1DYRK1AADORA2AMAPK13MAPK12 | |
| SCHEMBL3456003 | 0.85 | ADORA2A (0.43) | RAF1DYRK1AADORA2AMAPK13MAPK12 | |
| SCHEMBL5448755 | 0.83 | ADORA2A (0.52) | RAF1DYRK1AADORA2AMAPK13MAPK12 | |
| SCHEMBL3457100 | 0.81 | ADORA2A (0.50) | RAF1DYRK1AADORA2AMAPK13MAPK12 | |
| SCHEMBL5449809 | 0.80 | ADORA2A (0.47) | RAF1DYRK1AADORA2AMAPK13MAPK12 | |
| SCHEMBL5458678 | 0.80 | ADORA2A (0.47) | RAF1DYRK1AADORA2AMAPK13MAPK12 | |
| SCHEMBL3057933 | 0.73 | MAPK14 (0.55) | RAF1ADORA2AMAPK13MAPK12MAPK11 | |
| SCHEMBL5189460 | 0.72 | USP2 (0.46) | RAF1DYRK1AADORA2AMAPK13MAPK12 | |
| SCHEMBL5447978 | 0.71 | ADORA1 (0.69) | RAF1ADORA2AMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2246344-A1 | Pyrimidine compounds and medicinal composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | HARADA HITOSHI | 2009-01-29 | — | — | US | disclosed |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | HARADA HITOSHI | 2009-01-29 | — | — | US | disclosed |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | HARADA HITOSHI | 2009-01-29 | — | — | US | disclosed |
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-20050004149-A1 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1439175-A1 | PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | CBR3, AHR, HCCS | RAF1 434/4885DYRK1A 4130/4885ADORA2A 539/4885 |
| US-20050004149-A1 | Pyrimidine compound and medicinal composition thereof | ADORA2B, ADORA2A, ADORA3 | RAF1 1446/4885DYRK1A 1944/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.